Abstract
Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-17 |
| Number of pages | 17 |
| Journal | Cancer Innovation |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2023 |
| Externally published | Yes |
Keywords
- breast cancer
- chemotherapy
- endocrine therapy
- immunotherapy
- targeted therapy
ASJC Scopus subject areas
- Oncology
- Drug Discovery
- Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
- Cancer Research
- Pharmacology (medical)